CareDx shares surged after the transplant diagnostics company beat third-quarter expectations, reported stronger testing growth and raised its 2026 revenue and adjusted EBITDA forecasts.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.